REG - Physiomics PLC - Physiomics Awarded Contract Extension

PhysiomicsAnnouncement

29/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250529:nRSc4954Ka&default-theme=true

RNS Number : 4954K  Physiomics PLC  29 May 2025

29 May 2025

 

Physiomics plc

("Physiomics" or the "Company")

 

Physiomics Awarded Contract Extension

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, is pleased to announce a sizeable contract
extension award with an existing large pharma client.

The project builds upon the contract award announced on 13 June 2024, where
the Company's proprietary Virtual Tumour platform has been used to model the
client's targeted oncology agents in combination with other modalities so to
help inform dose and scheduling decisions. This contract extension allows the
continuation of this work and further supports the client's expansion into new
oncology indications. The project is valued at £143,780 and is projected to
complete over the next six months, with the majority of the contract's value
being recognised in the financial year ending 30 June 2026.

 

Dr Peter Sargent, CEO of Physiomics, commented:

"We are thrilled to have been awarded this sizeable contract extension. The
award is testament to the continuation of our deep relationship with this
large pharma client and the positive impact we have on their oncology
portfolio. It also reflects the power and utility of our Virtual Tumour
platform in supporting novel oncology therapies, especially in modelling
therapies used in combination with other modalities."

 

For more information about Physiomics and its services, please visit
www.physiomics.co.uk (http://www.physiomics.co.uk) .

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting-edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 100 commercial projects, with over 125 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK. 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTUWRBRVWUVUAR